Сравнение
Maridebart Cafraglutide vs. Mazdutide
Два пептида рядом — идентичность, доказательная база, правовой статус и известные нежелательные явления.
Идентичность
Категория
Метаболизм
Метаболизм
Номер CAS
нет данных
2259884-03-0
Молекулярная масса
нет данных
4790 g/mol
Период полувыведения
нет данных
132 h
Последовательность
нет данных
synthetisches Oxyntomodulin-Analogon (39 Aminosäuren) mit FettsäureseitenketteМеханизм действия
Maridebart Cafraglutide
MariTide combines GLP-1 receptor agonism with GIP receptor antagonism in an antibody-peptide conjugate. Its long duration of action allows infrequent (monthly) dosing.
Mazdutide
Mazdutide is a dual agonist at the GLP-1 and glucagon receptors and is structurally derived from the gut hormone oxyntomodulin. The GLP-1 component mediates glucose-dependent insulin secretion, inhibition of glucagon secretion at elevated blood glucose, and modulation of appetite and gastric emptying. The glucagon component can influence energy expenditure and hepatic lipid and glucose metabolism. A fatty-acid side chain enables albumin binding and the weekly administration interval.
Доказательная база
Наивысшая доказательность
РКИ на людях
РКИ на людях
Исследования
1
4
из них на людях
1
4
Зафиксированные эффекты
2
4
Открытые противоречия
0
0
Задокументированные нежелательные явления
1
0
Правовой статус
Полные записи
Frequently asked questions
- What is the difference between Maridebart Cafraglutide and Mazdutide?
- Maridebart Cafraglutide is classified as "Метаболизм", while Mazdutide is classified as "Метаболизм". Maridebart Cafraglutide: Maridebart cafraglutide (MariTide, Amgen) is a bispecific molecule: a GLP-1 receptor agonist combined with a GIP receptor antagonist, designed for monthly dosing; in phase 3 for obesity. Mazdutide: Synthetic oxyntomodulin analogue that simultaneously activates the GLP-1 and glucagon receptors (dual agonist). Developed by Innovent Biologics and Eli Lilly. In China the NMPA approved mazdutide on 27 June 2025 for chronic weight management; a further filing for type 2 diabetes is under review in China. Outside China the substance remains in clinical development. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Maridebart Cafraglutide or Mazdutide?
- The highest available evidence level is "РКИ на людях" for Maridebart Cafraglutide and "РКИ на людях" for Mazdutide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Maridebart Cafraglutide and Mazdutide in Germany and the United States?
- Германия: Maridebart Cafraglutide — Не одобрено, Mazdutide — Только для исследований. США: Maridebart Cafraglutide — Не одобрено, Mazdutide — Только для исследований. These are factual summaries with source and review date on the individual pages.